FCA
RCUS icon

FinTrust Capital Advisors’s Arcus Biosciences RCUS Stock Holding History

FinTrust Capital Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-23
Closed -$476 – 1328
2023
Q2 		$476 Hold
23
– – ﹤0.01% 1146
2023
Q1 		$476 Hold
23
– – ﹤0.01% 1137
2022
Q4 		$476 Buy
+23
New +$633 ﹤0.01% 1134

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FinTrust Capital Advisors's RCUS Position: Q3 2023 in Review

FinTrust Capital Advisors sold out of Arcus Biosciences (RCUS) in Q3 2023, closing a stake of 23 shares — an estimated $476 sold.

FinTrust Capital Advisors first reported a position in RCUS in Q4 2022 and held it in 3 quarters. The position peaked at $476 in Q2 2023. 187 funds tracked by Wall St. Rank hold RCUS as of Q3 2023.

  • FinTrust Capital Advisors reported no remaining Arcus Biosciences position as of Q3 2023 after selling out during the quarter.
  • FinTrust Capital Advisors sold 23 Arcus Biosciences shares in Q3 2023, an estimated $476.
  • FinTrust Capital Advisors first reported a position in Arcus Biosciences in Q4 2022 and held it in 3 quarters.
  • FinTrust Capital Advisors's Arcus Biosciences position peaked at $476 in Q2 2023.
  • 187 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2023.

Based on FinTrust Capital Advisors's 13F filing for Q3 2023, filed 24 Oct 2023.